Sign in →

Test Code NMOE Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum

Additional Codes

Epic Order Name: NMO EVALUATION W/REFLEX TO TITER (aka NMOE)
Sunquest Order Code: NMOE
Epic Px Code: LAB2894

Useful For

Diagnosis of a neuromyelitis optica spectrum disorder (NMOSD)

 

Diagnosis of autoimmune AQP4 channelopathy

 

Diagnosis of neuromyelitis optica (NMO)

 

Distinguishing NMOSD from multiple sclerosis early in the course of disease

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
NMOTS NMO/AQP4 FACS Titer, S No No

Testing Algorithm

When the results of this assay require further evaluation, NMOTS / Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Titer Assay, Serum will be performed at an additional charge.

Method Name

Flow Cytometry

Reporting Name

NMO/AQP4 FACS, S

Specimen Type

Serum


Ordering Guidance


 



Specimen Required


Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 3 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK

Reference Values

Negative

Day(s) Performed

Monday, Tuesday, Thursday

Report Available

5 to 8 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

86053

86053-titer (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
NMOFS NMO/AQP4 FACS, S 43638-6

 

Result ID Test Result Name Result LOINC Value
38324 NMO/AQP4 FACS, S 43638-6

Secondary ID

38324

Forms

If not ordering electronically, complete, print, and send Neurology Specialty Testing Client Test Request (T732) with the specimen.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.